Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

Preliminary results of earlier steroid use with axicabtagene ciloleucel in...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )

FORTE trial results: KRd with or without transplantation in newly diagnosed...

Dr Francesca Gay - University Hospital City of Health and Science of Turin...

FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status ( Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy )

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti...

Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )

Subcutaneous versus intravenous daratumumab administration in patients with...

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

$Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )$

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital...

Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )

More from ecancer